Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer

  • D. Klaus
Conference paper


Das Wirkprofil der ACE-Hemmer weist entsprechend den Wirkungen von Angiotensin II ein weites Spektrum auf.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circul Res 57: 84–95CrossRefGoogle Scholar
  2. 2.
    Pfeffer MA, Lamas GA, Vaughu DE, Parisi AE, Braunwald E (1988) Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319: 80–86PubMedCrossRefGoogle Scholar
  3. 3.
    Portaluppi F, Padula A, Alfiero R, Rizzo A (1985) Ergometric evaluation of the effects of captopril in hypertensive patients with stable angina. J Hypertension 3 (Suppl II): 147 —148Google Scholar
  4. 4.
    The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316: 1429–1435CrossRefGoogle Scholar
  5. 5.
    Webster MWI, Fitzpatrick MA, Nickolls G, Ikram H, Wells JE (1985) Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 56: 566–569PubMedCrossRefGoogle Scholar
  6. 6.
    Asmar RG, Journo HJ, Lacolley PJ, Levy BI, Safar ME (1988) Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertension 6 (Suppl 3): S 33—S 39Google Scholar
  7. 7.
    Klaus D (1985) Regression der Linksherzhypertrophie beim arteriellen Blutdruck: Grundlagen, experimentelle und klinische Befunde. Z Kardiol 75 (Suppl 7): 153–169Google Scholar
  8. 8.
    Kannel WB, Gordon T, Castelli WP, Margolis JR (1970) ECG-left ventricular hypertrophy and risk of CHD. The Framingham Study. Am Int Med 72: 813Google Scholar
  9. 9.
    Santoni JP, Asmar RG, Bizot-Espiarch JG, Safar M (1989) Enregistrement ambulatoire de la pression artérielle lors d’un traitement par le perindopril. Arch Mal Cceur 82/1:51 — 56Google Scholar
  10. 10.
    Diamond JR, Karnovsky MJ (1988) Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917–924PubMedCrossRefGoogle Scholar
  11. 11.
    Anderson S, Meyer TW, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612–619PubMedCrossRefGoogle Scholar
  12. 12.
    Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer Taguma Y, Kitamoto Y, Futaki G, Ueda H, Takahashi H, Sasaki Y (1985) Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617–1620Google Scholar
  13. 13.
    Parving H-H, Hommel E, Schmidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 297: 1086–1091CrossRefGoogle Scholar
  14. 14.
    Mimram A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J (1988) Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertension 6: 619–923CrossRefGoogle Scholar
  15. 15.
    Textor SC, Gephardt GN, Bravo EW, Tarazi RC, Fouad FM, McMahon JT (1983) Membranous glomerulopathy associated with captopril therapy. Am J Med 74: 705–712PubMedCrossRefGoogle Scholar
  16. 16.
    Parving H-M, Anderson AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet I: 1175–1179Google Scholar
  17. 17.
    Reisch C, Mann J, Ritz E (1987) Konversionsenzymhemmer in der antihypertensiven Behandlung niereninsuffizienter Patienten. Dtsch Med Wochenschr 112: 1249–1252PubMedCrossRefGoogle Scholar
  18. 18.
    Klaus D (1988) Der Stellenwert von Konversionsenzymhemmern in der Hypertoniebehandlung. Z Kardiol 77 (Suppl 3): 73–88PubMedGoogle Scholar
  19. 19.
    Berk BC, Vekshtein V, Gordon MH, Tsuda T (1989) Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 13: 305–314PubMedCrossRefGoogle Scholar
  20. 20.
    Levy BI, Michel J-B, Salzmann JL, Camilleri JP, Safar ME (1988) Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats. J Hypertension 6 (Suppl 3): S 23 —S 25Google Scholar
  21. 21.
    Christensen HRL, Nielsen H, Christensen KL, Jespersen LT, Mulvany MJ (1988) Longterm hypotensive effects of an angiotensin converting enzyme inhibitor in spontaneously hypertensive rats: is there a role for vascular structure? J Hypertension 1988 6 (Suppl 3): S27 — S31Google Scholar
  22. 22.
    Heagerty AM, Bund SJ, Alkjaer C (1988) Effects of drug treatment on human resistance arteriole morphology: direct evidence for structural remodelling of resistance vessels. Lancet II: 1209–1212Google Scholar
  23. 23.
    Santoni J-P, Asmar R, Safar ME (1989) Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension. Clin Exp (Theory and Practice) All (Suppl 2 ): 535–544Google Scholar
  24. 24.
    Hostetter TM, Renke MG, Brenner GM (1982) The case for intrarenal hypertension in the initation and progression of diabetic and other glomerulopathies. Am J Med 72: 375380Google Scholar
  25. 25.
    Speirs CJ, Mollery CT, Inman WHW, Rawson NSB, Wilton LV (1988) Postmarketing surveillance of enalapril, II: Investigation of the potential role of enalapril in deaths with renal failure. Br Med J 297: 830–832Google Scholar
  26. 26.
    Cleland JGF, Dargie HJ, Ball SG, Gillen G, Ford I, Robertson JIS (1985) Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 54: 305–312PubMedCrossRefGoogle Scholar
  27. 27.
    Kramer BL, Massie BM, Topic N (1983) Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 67: 807–816PubMedCrossRefGoogle Scholar
  28. 28.
    Dzau VJ (1989) Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities, and hypotheses. J Hypertension 7: 933–936CrossRefGoogle Scholar
  29. 29.
    Safar ME (1989) Pulse pressure in essential hypertension: clinical and therapeutical implications. J Hypertension 7: 769–776CrossRefGoogle Scholar
  30. 30.
    Marre M, Chatellier G, Leblanc H, Menard J, Pussa P (1988) Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 297: 1092–1095CrossRefGoogle Scholar
  31. 31.
    Chobanian AV, Haudenschild CC, Nickerson C, Drago R (1990) Antiatherogenic effect of captopril in the Watanale heritable hyperlipidemic rat. Hypertension 15: 327–331PubMedCrossRefGoogle Scholar
  32. 32.
    Parving M-H, Hommel E, Nielsen MD, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. Br Med J 289: 533–536CrossRefGoogle Scholar
  33. 33.
    D. Klaus: Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer Schölkens BA, Becker RMA, Linz W (1988) Pharmakologische Beeinflussung des Konversionsenzyms — lokale und systemische Effekte an Herz und GeraBen. Z Kardiol 77 (Suppl 3 ): 13–21Google Scholar
  34. 34.
    Schilling H, Scheler F (1988) ACE-Hemmung, Nebenwirkungen und Risiken. Z Kardiol 77 (Suppl 3): 47–54PubMedGoogle Scholar
  35. 35.
    Björk S, Mulec H, Johnson SH, Nyberg G, Aurell M (1990) Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Br Med J 300: 904–907CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • D. Klaus

There are no affiliations available

Personalised recommendations